Bank of America ( BAC) rating reinstated at Goldman with a Buy. Estimate that the company has $22.5 billion in unrealized after-tax equity gains principally stemming from investments in China. See continued play on rapid growth in financial services in China and Brazil. Target at $63. CBS ( CBS) downgraded at Deutsche Bank from Buy to Hold. $33 price target. Soft ratings trends and poor local ad growth will offset any extra political demand. Estimates also cut. Forest Laboratories ( FRX) upgraded at Citigroup from Sell to Hold. Stock trades at just 11.2 times forward earnings, though the company still faces patent and earnings risks. $43 price target. Intuitive Surgical ( ISRG) initiated at Morgan Stanley with an equalweight rating, as the company sees little reason for multiple expansion from current levels. LifeCell ( LIFC) initiated at Morgan Stanley with an equalweight rating and $44 price target. Medicines ( MDCO) upgraded at UBS to Buy rating from Sell. Price target jumps to $23.50 from $17 and 2008 EPS estimates lowered to $0.35 from $0.43. Onyx Pharma ( ONXX) downgraded at Bear Stearns from Outperform to Peer Perform. $45 price target. Valuation call, as the company lacks significant catalysts heading into 2008. Oshkosh Truck ( OSK) coverage initiated at Goldman Sachs with a Buy rating. See strong earnings growth fueled by Defense business, with JLG acquisition adding attractive non-North America infrastructure growth. Price target at $70.